YPHA Stock Overview
Manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥9.35 |
| 52 Week High | JP¥11.50 |
| 52 Week Low | JP¥8.40 |
| Beta | 0.22 |
| 11 Month Change | -9.22% |
| 3 Month Change | -14.22% |
| 1 Year Change | -13.43% |
| 33 Year Change | -34.15% |
| 5 Year Change | n/a |
| Change since IPO | -36.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| YPHA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.1% | 1.4% | 0.8% |
| 1Y | -13.4% | -18.4% | 9.1% |
Return vs Industry: YPHA exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: YPHA underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| YPHA volatility | |
|---|---|
| YPHA Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YPHA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: YPHA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 14,754 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Astellas Pharma Inc. Fundamentals Summary
| YPHA fundamental statistics | |
|---|---|
| Market cap | €17.39b |
| Earnings (TTM) | €338.39m |
| Revenue (TTM) | €10.95b |
51.4x
P/E Ratio1.6x
P/S RatioIs YPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YPHA income statement (TTM) | |
|---|---|
| Revenue | JP¥1.77t |
| Cost of Revenue | JP¥322.95b |
| Gross Profit | JP¥1.45t |
| Other Expenses | JP¥1.39t |
| Earnings | JP¥54.75b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 30.58 |
| Gross Margin | 81.78% |
| Net Profit Margin | 3.09% |
| Debt/Equity Ratio | 61.2% |
How did YPHA perform over the long term?
See historical performance and comparison